Abstract
Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 639-651 |
| Number of pages | 13 |
| Journal | European Journal of Gastroenterology and Hepatology |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- brivanib
- everolimus
- hepatocellular carcinoma
- linifanib
- radiofrequency ablation
- ramucirumab
- sorafenib
- transarterial chemoembolization
- transplantation
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma : A European perspective. / Colombo, Massimo; Raoul, Jean Luc; Lencioni, Riccardo; Galle, Peter R.; Zucman-Rossi, Jessica; Bañares, Rafael; Seehofer, Daniel; Neuhaus, Peter; Johnson, Philip.
In: European Journal of Gastroenterology and Hepatology, Vol. 25, No. 6, 06.2013, p. 639-651.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma
T2 - A European perspective
AU - Colombo, Massimo
AU - Raoul, Jean Luc
AU - Lencioni, Riccardo
AU - Galle, Peter R.
AU - Zucman-Rossi, Jessica
AU - Bañares, Rafael
AU - Seehofer, Daniel
AU - Neuhaus, Peter
AU - Johnson, Philip
PY - 2013/6
Y1 - 2013/6
N2 - Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.
AB - Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the cancer stage, patient performance status, and liver function and requires a multidisciplinary approach and close cooperation among specialists for the best patient outcomes. Despite advances in surgical treatments and locoregional therapies, recurrence and liver failure remain significant challenges. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. The multikinase inhibitor sorafenib is the only approved targeted agent for advanced HCC, although promising results have been obtained with other targeted agents and combinations, and the results of ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, including molecular classification and validation of new molecular biomarkers, are required to improve the personalized treatment of HCC. This article provides an overview of HCC and was developed through a review of relevant literature, clinical trial data, and updated clinical guidelines.
KW - brivanib
KW - everolimus
KW - hepatocellular carcinoma
KW - linifanib
KW - radiofrequency ablation
KW - ramucirumab
KW - sorafenib
KW - transarterial chemoembolization
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=84877121118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877121118&partnerID=8YFLogxK
U2 - 10.1097/MEG.0b013e32835e33bb
DO - 10.1097/MEG.0b013e32835e33bb
M3 - Article
C2 - 23628963
AN - SCOPUS:84877121118
VL - 25
SP - 639
EP - 651
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
SN - 0954-691X
IS - 6
ER -